It- trattament għall- kanċer tal- pulmun jiddependi minn diversi fatturi, inkluż l- istadju tal- kanċer, it- tip taʼ kanċer tal- pulmun, u s- saħħa ġenerali tal- pazjent.
Xi għażliet komuni ta ' trattament jinkludu:
1. Kirurġija: Ħafna drabi din hija t- trattament preferut għall- kanċer tal- pulmun fl- ewwel stadju.
Il- kirurgu jneħħi t- tumur u porzjon żgħir taʼ tessut b'saħħtu madwaru.
2. Terapija bir- radjazzjoni: Ir- radjazzjoni b'enerġija għolja tintuża biex toqtol iċ- ċelloli tal- kanċer u tnaqqas it- tumuri.
Jista ' jintuża waħdu jew f' kombinazzjoni ma ' trattamenti oħra.
3. Kemoterapija: Dan it- trattament juża mediċini biex joqtlu ċ- ċelloli tal- kanċer.
Jista ' jingħata ġol- vina jew mill- ħalq, u spiss jintuża flimkien ma ' trattamenti oħra.
4. Terapija mmirata: Din it- trattament timmira lejn ġeni jew proteini speċifiċi li jikkontribwixxu għat- tkabbir u s- sopravivenza taċ- ċelloli tal- kanċer.
Ħafna drabi jintuża għal kanċer tal- pulmun avvanzat jew metastatiku.
5. Immunoterapija: Dan it- trattament jgħin lis- sistema immunitarja tirrikonoxxi u taffettwa ċ- ċelloli tal- kanċer.
Ħafna drabi jintuża għal kanċer tal- pulmun avvanzat jew metastatiku.
6. Terapija fotodinamika: Dan it- trattament juża mediċina attivata bid- dawl biex joqtol iċ- ċelloli tal- kanċer.
Ħafna drabi jintuża għal kanċer tal- pulmun fl- istadju bikri.
7. Terapija bil- protoni: Dan huwa tip taʼ terapija bir- radjazzjoni li tuża l- protoni minflok ir- raġġi X biex twassal ir- radjazzjoni lit- tumur.
Ħafna drabi jintuża għal kanċer tal- pulmun fl- istadju bikri.
8. Provi kliniċi: Il-pazjenti jistgħu jkunu eliġibbli biex jipparteċipaw fi provi kliniċi li jittestjaw trattamenti ġodda jew kombinazzjonijiet ta' trattamenti.
Huwa importanti li tiddiskuti l- aħjar għażliet ta ' trattament ma ' tim tal- kura tas- saħħa, peress li l- iktar pjan ta ' trattament effettiv jiddependi mis- sitwazzjoni speċifika tal- individwu.
Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.
Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.
Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.
Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.
Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.
Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.
Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.
Tneħħija ta ' responsabbiltà: mediku
Dan is-sit tal-web huwa pprovdut għal skopijiet edukattivi u ta' informazzjoni biss u ma jikkostitwixxix l-għoti ta' parir mediku jew servizzi professjonali.
L- informazzjoni pprovduta m'għandhiex tintuża għad- dijanjosi jew it- trattament taʼ problema jew marda tas- saħħa, u dawk li jfittxu parir mediku personali għandhom jikkonsultaw maʼ tabib liċenzjat.
Jekk jogħġbok innota li n-netwerk newrali li jiġġenera t-tweġibiet għall-mistoqsijiet, huwa speċjalment mhux preċiż meta niġu għal kontenut numeriku. Pereżempju, in-numru ta' nies dijanjostikati b'marda speċifika.
Dejjem fittex il-parir tat-tabib tiegħek jew ta' fornitur tas-saħħa kwalifikat ieħor dwar kundizzjoni medika. Qatt ma tinjora l-parir mediku professjonali jew id-dewmien fit-tfittxija tiegħu minħabba xi ħaġa li qrajt f'dan il-websajt. Jekk taħseb li tista' jkollok emerġenza medika, ċempel 911 jew mur l-eqreb kamra tal-emerġenza immedjatament. L-ebda relazzjoni bejn tabib u pazjent ma tinħoloq minn dan il-websajt jew l-użu tagħha. La BioMedLib u lanqas l-impjegati tagħha, u lanqas kwalunkwe kontributur għal dan il-websajt, ma jagħmel xi rappreżentazzjonijiet, espressi jew impliċiti, fir-rigward tal-informazzjoni pprovduta hawnhekk jew għall-użu tagħha.
Riżerva ta' responsabbiltà: drittijiet tal-awtur
L-Att dwar id-Drittijiet tal-Awtur tal-Millennju Diġitali tal-1998, 17 U.S.C. § 512 (il-"DMCA") jipprovdi rikors għas-sidien tad-drittijiet tal-awtur li jemmnu li materjal li jidher fuq l-Internet jikser id-drittijiet tagħhom skont il-liġi tad-drittijiet tal-awtur tal-Istati Uniti.
Jekk temmen b'bona fidi li kwalunkwe kontenut jew materjal magħmul disponibbli b'rabta mal-websajt jew is-servizzi tagħna jikser id-drittijiet tal-awtur tiegħek, inti (jew l-aġent tiegħek) tista' tibgħatilna avviż li jitlob li l-kontenut jew il-materjal jitneħħa, jew li l-aċċess għalih jiġi mblukkat.
Id-DMCA teħtieġ li n-notifika tiegħek ta' ksur allegat tad-drittijiet tal-awtur tinkludi l-informazzjoni li ġejja: (1) deskrizzjoni tax-xogħol protett bid-drittijiet tal-awtur li huwa s-suġġett ta' ksur allegat; (2) deskrizzjoni tal-kontenut allegatament li jikser id-drittijiet tal-awtur u informazzjoni suffiċjenti biex inkunu nistgħu nsibu l-kontenut; (3) informazzjoni ta' kuntatt għalik, inkluż l-indirizz tiegħek, in-numru tat-telefon u l-indirizz tal-email; (4) dikjarazzjoni minnek li għandek twemmin ta' fidi tajba li l-kontenut bil-mod li dwaru l-ilment ġie ppreżentat mhuwiex awtorizzat mid-detentur tad-drittijiet tal-awtur, jew mill-aġent tiegħu, jew mill-operazzjoni ta' kwalunkwe liġi;
(5) stqarrija minnek, iffirmata taħt il-piena ta' perjuri, li l-informazzjoni fin-notifika hija preċiża u li għandek l-awtorità li tinforza d-drittijiet tal-awtur li huma ddikjarati li ġew miksura;
u (6) firma fiżika jew elettronika tas-sid tad-drittijiet tal-awtur jew ta' persuna awtorizzata li taġixxi f'isem is-sid tad-drittijiet tal-awtur.
In-nuqqas li tinkludi l-informazzjoni kollha ta' hawn fuq jista' jwassal għal dewmien fit-trattament tal-ilment tiegħek.
Kuntatt
Jekk jogħġbok ibgħatilna email b'kull mistoqsija / suġġeriment.
How to treat lung cancer?
The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.
Some common treatment options include:
1. Surgery: This is often the preferred treatment for early-stage lung cancer.
The surgeon removes the tumor and a small portion of healthy tissue around it.
2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.
It can be used alone or in combination with other treatments.
3. Chemotherapy: This treatment uses drugs to kill cancer cells.
It can be given intravenously or or orally, and is often used in combination with other treatments.
4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.
It is often used for advanced or metastatic lung cancer.
5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.
It is often used for advanced or metastatic lung cancer.
6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.
It is often used for early-stage lung cancer.
7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.
It is often used for early-stage lung cancer.
8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.
It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Madwar
BioMedLib juża kompjuters awtomatizzati (algoritmi ta' tagħlim tal-magni) biex jiġġenera koppji ta' mistoqsijiet u tweġibiet.
Aħna nibdew b'35 miljun pubblikazzjoni bijomedika ta' PubMed/Medline. Ukoll, paġni tal-web ta' RefinedWeb.
